益赛普、柳氮磺砒碇治疗强直性脊柱炎对照研究

Etanercept versus sulfasalazine in the treatment of ankylosing spondylitis

目的 通过与柳氮磺砒啶（SSZ）进行对照,研究益赛普对强直性脊柱炎（AS）的疗效.方法 选取处于活动期的AS患者40例,分别给予益赛普（50 mg/周）及柳氮磺砒碇（2.0g/日）进行治疗,总疗程为24周,对两药在12、24周时疗效及观察指标进行评估.结果 益赛普在12、24周时的有效率分别为90.0%,95.0%,柳氮磺吡啶都为70.0%.显示益赛普能显著改善临床实验观察指标（P〈0.05）,耐受性与柳氮磺吡啶差异无显著性（P〉0.5）. 结论益赛普是一种新型有效且安全的治疗AS的药物.

Objective To explore the efficacy of etanercept for ankylosiong spondylitis （ AS ） by comparing with sulfasalazine. Methods 40 patients with active AS were randomly assigned to receive etanercept （ 50mg weekly ） or sulfasalazine （ 2.0g daily ） for 24weeks. Efficacy was assessed at weeks 12 and 24 in both groups. Results The effectiveness rate ofetanercept was 90% at week 12 and 95% at week 24,while sulfasalazine was 70% at weeks 12 and 24. Etanercept was similar with sulfasalazine in drug tolerance.Conclusions Etanercept is a new effecitve and more safe drug.